David Bennett1, Antonella Fossi2, Giuseppina Chiarello2, Rosa Metella Refini2, Luca Luzzi3, Piero Paladini3, Maria Materozzi4, Natale Figura4, Ranuccio Nuti4, Paola Rottoli2. 1. Respiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Viale Bracci, 16, 53100, Siena, Italy. david.btt@gmail.com. 2. Respiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Viale Bracci, 16, 53100, Siena, Italy. 3. Thoracic Surgery, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Siena, Italy. 4. Internal Medicine, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, Siena, Italy.
Abstract
BACKGROUND: Helicobacter pylori (HP) is a spiral, gram-negative, microaerophilic bacterium that colonises the human gastric mucosa and is associated with gastrointestinal and extragastrointestinal disorders. Since no data are yet available on HP infection in lung transplant patients, we evaluated the prevalence and impact of HP infection in a population of such patients. METHODS: Sixty-seven lung transplant patients were enrolled in the study (35 females and 32 males, age 48.4 ± 13.3 years), 54 underwent bilateral and 13 single lung transplant. Serum antibodies against HP and CagA were assayed in all subjects. RESULTS: The prevalence of HP infection in lung transplant patients was similar to that in the general population (49.25% vs. 51.4%), whereas HP-positive patients showed lower CagA positivity (9% vs. 50.2%, p < 0.0001). There was a higher prevalence of HP infection in patients who underwent lung transplant because of pulmonary fibrosis (p = 0.049), and a lower prevalence in COPD patients (p = 0.011). No correlation was found between HP infection in lung transplant patients and graft outcome. No differences in primary graft dysfunction, acute rejection or bronchiolitis obliterans syndrome-free survival were found. However, more patients who required three or more post-transplant re-hospitalisations were observed among HP-positive patients. CONCLUSIONS: The prevalence of HP infection in lung transplant patients was comparable to that of the general population and to that reported in heart and kidney transplant recipients. It did not seem to impact short-, mid- or long-term lung allograft outcome. H. pylori infection did not prove to be clinically relevant in lung transplant patients.
BACKGROUND:Helicobacter pylori (HP) is a spiral, gram-negative, microaerophilic bacterium that colonises the humangastric mucosa and is associated with gastrointestinal and extragastrointestinal disorders. Since no data are yet available on HP infection in lung transplant patients, we evaluated the prevalence and impact of HP infection in a population of such patients. METHODS: Sixty-seven lung transplant patients were enrolled in the study (35 females and 32 males, age 48.4 ± 13.3 years), 54 underwent bilateral and 13 single lung transplant. Serum antibodies against HP and CagA were assayed in all subjects. RESULTS: The prevalence of HP infection in lung transplant patients was similar to that in the general population (49.25% vs. 51.4%), whereas HP-positive patients showed lower CagA positivity (9% vs. 50.2%, p < 0.0001). There was a higher prevalence of HP infection in patients who underwent lung transplant because of pulmonary fibrosis (p = 0.049), and a lower prevalence in COPDpatients (p = 0.011). No correlation was found between HP infection in lung transplant patients and graft outcome. No differences in primary graft dysfunction, acute rejection or bronchiolitis obliterans syndrome-free survival were found. However, more patients who required three or more post-transplant re-hospitalisations were observed among HP-positive patients. CONCLUSIONS: The prevalence of HP infection in lung transplant patients was comparable to that of the general population and to that reported in heart and kidney transplant recipients. It did not seem to impact short-, mid- or long-term lung allograft outcome. H. pylori infection did not prove to be clinically relevant in lung transplant patients.
Authors: C Guarneri; J Lotti; M Fioranelli; M G Roccia; T Lotti; F Guarneri Journal: J Biol Regul Homeost Agents Date: 2017 APR-JUN Impact factor: 1.711
Authors: Rinaldo Pellicano; Davide G Ribaldone; Sharmila Fagoonee; Marco Astegiano; Giorgio M Saracco; Francis Mégraud Journal: Panminerva Med Date: 2016-12 Impact factor: 5.197
Authors: Michael Kreuter; Detlef Kirsten; Thomas Bahmer; Roland Penzel; Martin Claussen; Svenja Ehlers-Tenenbaum; Thomas Muley; Karin Palmowski; Monika Eichinger; Marta Leider; Felix J F Herth; Klaus F Rabe; Iris Bittmann; Arne Warth Journal: Respiration Date: 2015-12-09 Impact factor: 3.580